Advances in modulating thermosensory TRP channels

Expert Opinion on Therapeutic Patents

Volumn 22, Issue 9, 2012, Pages 999-1017

  Ferrer Montiel, Antonio ^a   Fernández Carvajal, Asia ^a   Planells Cases, Rosa ^a   Fernández Ballester, Gregorio ^a   González Ros, José Manuel ^a   Messeguer, Àngel ^b   González Muñiz, Rosario ^b  

^a MIGUEL HERNÁNDEZ UNIVERSITY   (Spain)

^b CSIC   (Spain)

Author keywords

Cancer; Inflammation; Ion channel; Nociception; Pain; Sensory

Indexed keywords

(5 TERT BUTYL 2,3 DIHYDRO 1H INDEN 1 YL) 3 (1H INDAZOL 4 YL)UREA; 1 (2 BROMOPHENYL) 3 [1 (5 TRIFLUOROMETHYL 2 PYRIDINYL) 3 PYRROLIDINYL]UREA; ANALGESIC AGENT; CAPSAICIN; CB 625; CIS CAPSAICIN; D 3263; DILMAPIMOD; DWP 05195; GRC 15300; GRC 17536; JNJ 39439335; JTS 653; MK 2295; PAC 1028; PHE 337; PIPERINE; TRANSIENT RECEPTOR POTENTIAL CHANNEL; TRANSIENT RECEPTOR POTENTIAL CHANNEL 1; TRANSIENT RECEPTOR POTENTIAL CHANNEL 2; TRANSIENT RECEPTOR POTENTIAL CHANNEL 3; TRANSIENT RECEPTOR POTENTIAL CHANNEL 4; TRANSIENT RECEPTOR POTENTIAL CHANNEL A1; TRANSIENT RECEPTOR POTENTIAL CHANNEL AFFECTING AGENT; TRANSIENT RECEPTOR POTENTIAL CHANNEL M2; TRANSIENT RECEPTOR POTENTIAL CHANNEL M3; TRANSIENT RECEPTOR POTENTIAL CHANNEL M5; TRANSIENT RECEPTOR POTENTIAL CHANNEL M8; UNCLASSIFIED DRUG; UNINDEXED DRUG; WL 1001;

AMINO TERMINAL SEQUENCE; ANALGESIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; BURNING MOUTH SYNDROME; CLUSTER HEADACHE; DIABETIC NEUROPATHY; DYSPHAGIA; HUMAN; HYPERALGESIA; MIGRAINE; NEUROPATHIC PAIN; NOCICEPTIVE STIMULATION; NONHUMAN; OSTEOARTHRITIS; PAIN; PATENT; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSTHERPETIC NEURALGIA; POSTOPERATIVE PAIN; PROTEIN DOMAIN; RECTAL PAIN; REVIEW; RHINITIS; SOLID TUMOR; SPINAL GANGLION; SYMPATHETIC NERVE; TEMPERATURE SENSITIVITY; TOOTH PAIN;

ANIMALS; COLD TEMPERATURE; HOT TEMPERATURE; HUMANS; INFLAMMATION; NEOPLASMS; PAIN; PATENTS AS TOPIC; TRPV CATION CHANNELS;

EID: 84865470360     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2012.711320     Document Type: Review

References (178)

1. Venkatachalam K, Montell C. TRP channels. Annu Rev Biochem 2007;76:387-417 Excellent review on the superfamily of TRP channels.
2. Myers BR, Julius D. TRP channels structural biology: New roles for an old fold. Neuron 2007;54:847-50 (Pubitemid 46907514)
3. Moran MM, McAlexander MA, Biro T, et al. Transient receptor potential channels as therapeutic targets. Nat Rev Drug Discov 2011;10:601-20. This is an excellent review highlighting the importance of TRP channels as therapeutic targets.
4. Planells-Cases R, Valente P, Ferrer-Montiel A, et al. Complex regulation of TRPV1 and related thermo-TRPs: Implications for therapeutic intervention. Adv Exp Med Biol 2011;704:491-515
5. Planells-Cases R, Ferrer-Montiel A. Drug design and development through the vanilloids receptor. Expert Opinion Drug Discov 2007;2:1053-63 (Pubitemid 47354331)
6. Reilly R, McDonald H, Puttfarcken P, et al. Novel TRPV1 receptor antagonists that partially block acid activation: In vitro pharmacology predicts effects on core body temperature and in vivo efficacy. J Pharmacol Exp Ther 2012;342:416-28
7. Voight EA, Kort ME. Transient receptor potential vanilloid-1 antagonists: A survey of recent patent literature. Expert Opin Ther Patents 2010;20:1107-22
8. Sanz-Salvador L, Andres-Borderia A, Ferrer-Montiel A, et al. Agonist- and Ca2+-dependent desensitization of TRPV1 targets the receptor to lysosomes for degradation. J Biol Chem 2012;287:19462-71
9. Nash MS, McIntyre P, Groarke A, et al. BCTP, a classic polymodal inhibitor of TRPV1 with a reduced liability for hyperthermia, is analgesic and ameliorates visceral hypersensitivity. J Pharmacol Exp Ther 2012;In press PMD:22566669
10. Vidal-Mosquera M, Fernandez-Carvajal A, Moure A, et al. Triazine-based vanilloid 1 receptor open channel blockers: Design, synthesis, evaluation, and SAR analysis. J Med Chem 2011;54:7441-52. Description of an uncompetitive antagonist for TRPV1 channels.
11. Valente P, Fernandez-Carvajal A, Camprubi-Robles M, et al. Membrane-tethered peptides patterned after the TRP domain (TRPducins) selectively inhibit TRPV1 channel activity. FASEB J 2011;25:1628-40. Description of allosteric modulators for TRPV1 channels that provide a novel pharmacological strategy to modulate channel function.
12. Ponsati B, Carreno C, Curto-Reyes V, et al. An inhibitor of neuronal exocytosis (DD04107) displays long-lasting in vivo activity against chronic inflammatory and neuropathic pain. J Pharmacol Exp Ther 2012;341:634-45. This manuscript reports how modulation of receptor levels may be used as a valuable therapeutic strategy.
13. Caterina MJ, Rosen TA, Tominaga M, et al. A capsaicin-receptor homologue with a high threshold for noxious heat. Nature 1999;398:436-41 (Pubitemid 29180377)
14. Kojima I, Nagasawa MTRP. Ion channel function in sensory transduction and cellular signaling cascades. CRC Press; Boca Raton (FL): 2007
15. Tominaga M, Caterina MJ, Malmberg AB, et al. The cloned capsaicin receptor integrates multiple pain-producing stimuli. Neuron 1998;21:531-43 (Pubitemid 28475505)
16. Boels K, Glassmeier G, Herrmann D, et al. The neuropeptide head activator induces activation and translocation of the growth-factor-regulated Ca(2+)- permeable channel GRC. J Cell Sci 2001;114:3599-606 (Pubitemid 33041042)
17. Iwata Y, Katanosaka Y, Arai Y, et al. A novel mechanism of myocyte degeneration involving the Ca2 +-permeable growth factor-regulated channel. J Cell Biol 2003;161:957-67 (Pubitemid 36718428)
18. Monet M, Gkika D, Lehen'kyi V, et al. Lysophospholipids stimulate prostate cancer cell migration via TRPV2 channel activation. Biochim Biophys Acta 2009;1793:528-39
19. Shibasaki K, Murayama N, Ono K, et al. TRPV2 enhances axon outgrowth through its activation by membrane stretch in developing sensory and motor neurons. J Neurosci 2010;30:4601-12
20. Qin N, Neeper MP, Liu Y, et al. TRPV2 is activated by cannabidiol and mediates CGRP release in cultured rat dorsal root ganglion neurons. J Neurosci 2008;28:6231-8
21. Neeper MP, Liu Y, Hutchinson TL, et al. Activation properties of heterologously expressed mammalian TRPV2: Evidence for species dependence. J Biol Chem 2007;282:15894-902 (Pubitemid 47093309)
22. Juvin V, Penna A, Chemin J, et al. Pharmacological characterization and molecular determinants of the activation of transient receptor potential V2 channel orthologs by 2-aminoethoxydiphenyl borate. Mol Pharmacol 2007;72:1258-68 (Pubitemid 350012599)
23. Penna A, Juvin V, Chemin J, et al. PI3-kinase promotes TRPV2 activity independently of channel translocation to the plasma membrane. Cell Calcium 2006;39:495-507
24. Lewinter RD, Skinner K, Julius D, et al. Immunoreactive TRPV-2 (VRL-1), a capsaicin receptor homolog, in the spinal cord of the rat. J Comp Neurol 2004;470:400-8 (Pubitemid 38240941)
25. Ichikawa H, Sugimoto T. VRL-1 immunoreactivity in the rat cranial autonomic ganglia. Neuroreport 2001;12:1597-9 (Pubitemid 32521470)
26. Lewinter RD, Scherrer G, Basbaum AI. Dense transient receptor potential cation channel, vanilloid family, type 2 (TRPV2) immunoreactivity defines a subset of motoneurons in the dorsal lateral nucleus of the spinal cord, the nucleus ambiguus and the trigeminal motor nucleus in rat. Neuroscience 2008;151:164-73
27. Inada H, Iida T, Tominaga M. Different expression patterns of TRP genes in murine B and T lymphocytes. Biochem Biophys Res Commun 2006;350:762-7 (Pubitemid 44547911)
28. Hisanaga E, Nagasawa M, Ueki K, et al. Regulation of calcium-permeable TRPV2 channel by insulin in pancreatic beta-cells. Diabetes 2009;58:174-84
29. Link TM, Park U, Vonakis BM, et al. TRPV2 has a pivotal role in macrophage particle binding and phagocytosis. Nat Immunol 2010;11:232-9
30. Muraki K, Iwata Y, Katanosaka Y, et al. TRPV2 is a component of osmotically sensitive cation channels in murine aortic myocytes. Circ Res 2003;93:829-38 (Pubitemid 37363057)
31. Shimosato G, Amaya F, Ueda M, et al. Peripheral inflammation induces up-regulation of TRPV2 expression in rat DRG. Pain 2005;119:225-32 (Pubitemid 41752983)
32. Frederick J, Buck ME, Matson DJ, et al. Increased TRPA1, TRPM8, and TRPV2 expression in dorsal root ganglia by nerve injury. Biochem Biophys Res Commun 2007;358:1058-64 (Pubitemid 46828995)
33. Gaudet AD, Williams SJ, Hwi LP, et al. Regulation of TRPV2 by axotomy in sympathetic, but not sensory neurons. Brain Res 2004;1017:155-62 (Pubitemid 38917155)
34. Park U, Vastani N, Guan Y, et al. TRP vanilloid 2 knock-out mice are susceptible to perinatal lethality but display normal thermal and mechanical nociception. J Neurosci 2011;31:11425-36
35. Caprodossi S, Lucciarini R, Amantini C, et al. Transient receptor potential vanilloid type 2 (TRPV2) expression in normal urothelium and in urothelial carcinoma of human bladder: Correlation with the pathologic stage. Eur Urol 2008;54:612-20
36. Nabissi M, Morelli MB, Amantini C, et al. TRPV2 channel negatively controls glioma cell proliferation and resistance to Fas-induced apoptosis in ERK-dependent manner. Carcinogenesis 2010;31:794-803
37. Liu G, Xie C, Sun F, et al. Clinical significance of transient receptor potential vanilloid 2 expression in human hepatocellular carcinoma. Cancer Genet Cytogenet 2010;197:54-9
38. Oncomethylome Sciences S. Detection and prognosis of lung cancer. WO105549; 2009
39. Pilarsky C, Winter C, Kristansen G, et al. Gene expression markers for the prediction of the duration of survival of pancreatic carcinoma patients. DE102010043541A120110622; 2011
40. Vriens J, Appendino G, Nilius B. Pharmacology of vanilloid transient receptor potential cation channels. Mol Pharmacol 2009;75:1262-79 Excellent review on the pharmacology of TRPV channels.
41. Jpn.Kokai Tokkyo Koho. Peptide fragments of the cation channel TRPV2 that can repress the expression of the TRPV2 gene and therapeutic application. 2011
42. Janssen Pharmaceutica NV. Canine transient receptor potential V2 and methods of screening for TRPV2 channel modulators. WO109596; 2008
43. Janssen Pharmaceutica NV. Composition and methods for identifying modulators of TRPV2. WO053526; 2007
44. Smith GD, Gunthorpe MJ, Kelsell RE, et al. TRPV3 is a temperature-sensitive vanilloid receptor-like protein. Nature 2002;418:186-90 (Pubitemid 34773773)
45. Xu H, Ramsey IS, Kotecha SA, et al. TRPV3 is a calcium-permeable temperature-sensitive cation channel. Nature 2002;418:181-6 (Pubitemid 34773772)
46. Xu H, Delling M, Jun JC, et al. Oregano, thyme and clove-derived flavors and skin sensitizers activate specific TRP channels. Nat Neurosci 2006;9:628-35 (Pubitemid 44012260)
47. Peier AM, Reeve AJ, Andersson DA, et al. A heat-sensitive TRP channel expressed in keratinocytes. Science 2002;296:2046-9 (Pubitemid 34627531)
48. Mandadi S, Roufogalis BD. ThermoTRP channels in nociceptors: Taking a lead from capsaicin receptor TRPV1. Curr Neuropharmacol 2008;6:21-38 (Pubitemid 351513471)
49. Cheng X, Jin J, Hu L, et al. TRP channel regulates EGFR signaling in hair morphogenesis and skin barrier formation. Cell 2010;141:331-43
50. Lin Z, Chen Q, Lee M, et al. Exome sequencing reveals mutations in TRPV3 as a cause of olmsted syndrome. Am J Hum Genet 2012;90:558-64
51. Moqrich A, Hwang SW, Earley TJ, et al. Impaired thermosensation in mice lacking TRPV3, a heat and camphor sensor in the skin. Science 2005;307:1468-72 (Pubitemid 40321945)
52. Huang SM, Li X, Yu Y, et al. TRPV3 and TRPV4 ion channels are not major contributors to mouse heat sensation. Mol Pain 2011;7:37-43
53. Stuart Bevan PGPMAPAPCS. Transient Receptor Potential channel TRPV3 and its use. US7396910; 2006
54. Facer P, Casula MA, Smith GD, et al. Differential expression of the capsaicin receptor TRPV1 and related novel receptors TRPV3, TRPV4 and TRPM8 in normal human tissues and changes in traumatic and diabetic neuropathy. BMC Neurol 2007;7:11-23
55. Gopinath P, Wan E, Holdcroft A, et al. Increased capsaicin receptor TRPV1 in skin nerve fibres and related vanilloid receptors TRPV3 and TRPV4 in keratinocytes in human breast pain. BMC Womens Health 2005;5:2-11
56. Moussaieff A, Rimmerman N, Bregman T, et al. Incensole acetate, an incense component, elicits psychoactivity by activating TRPV3 channels in the brain. Faseb J 2008;22:3024-34
57. Carreno O, Corominas R, Fernandez-Morales J, et al. SNP variants within the vanilloid TRPV1 and TRPV3 receptor genes are associated with migraine in the Spanish population. Am J Med Genet B Neuropsychiatr Genet 2012;159B:94-103
58. Hydra Biosciences I. Compounds for modulating TRPV3 function. WO056124; 2007
59. Glenmark Pharmaceuticals SA. Chromane derivatives as TRPV3 modulators. WO004379; 2010
60. Glenmark Pharmaceuticals SA. Chromane derivatives as TRPV3 modulators. WO084034; 2009
61. Glenmark Pharmaceuticals SA. Fused pyrimidine derivatives as TRPV3 modulators. WO109987; 2009
62. Glenmark Pharmaceuticals SA. Fused pyrimidineone compounds as TRPV3 modulators. WO130560; 2009
63. Glenmark Pharmaceuticals SA. Chromenone derivatives as TRPV3 antagonists. WO055384; 2010
64. Glenmark Pharmaceuticals SA. Fused imidazole carboxamides as TRPV3 modulators. WO070452; 2010
65. Glenmark Pharmaceuticals SA. Fused imidazole derivatives as TRPV3 antagonist. WO073128; 2010
66. Abbott Laboratories. Novel TRPV3 modulators. WO019315; 2012
67. Guler AD, Lee H, Iida T, et al. Heat-evoked activation of the ion channel, TRPV4. J Neurosci 2002;22:6408-14 (Pubitemid 35386397)
68. Liedtke W, Choe Y, Marti-Renom MA, et al. Vanilloid receptor-related osmotically activated channel (VR-OAC), a candidate vertebrate osmoreceptor. Cell 2000;103:525-35
69. Strotmann R, Harteneck C, Nunnenmacher K, et al. OTRPC4, a nonselective cation channel that confers sensitivity to extracellular osmolarity. Nat Cell Biol 2000;2:695-702
70. Vriens J, Watanabe H, Janssens A, et al. Cell swelling, heat, and chemical agonists use distinct pathways for the activation of the cation channel TRPV4. Proc Natl Acad Sci USA 2004;101:396-401 (Pubitemid 38084261)
71. Birder L, Kullmann FA, Lee H, et al. Activation of urothelial transient receptor potential vanilloid 4 by 4alpha-phorbol 12,13-didecanoate contributes to altered bladder reflexes in the rat. J Pharmacol Exp Ther 2007;323:227-35 (Pubitemid 47443274)
72. Vergnolle N, Cenac N, Altier C, et al. A role of transient receptor potential vanilloid 4 in tonicity-induced neurogenic inflammation. Br J Pharmacol 2010;159:1161-73
73. Delany NS, Hurle M, Facer P, et al. Identification and characterization of a novel human vanilloid receptor-like protein, VRL-2. Physiol Genomics 2001;4:165-74 (Pubitemid 33676692)
74. Vriens J, Owsianik G, Fisslthaler B, et al. Modulation of the Ca2+ permeable cation channel TRPV4 by cytochrome P450 epoxygenases in vascular endothelium. Circ Res 2005;97:908-15 (Pubitemid 41552676)
75. Shimosato G, Amaya F, Ueda M, et al. Peripheral inflammation induces up-regulation of TRPV4 expression in rat DRG. Pain 2005;119:225-32 (Pubitemid 41752983)
76. Vincent F, Acevedo A, Nguyen MT, et al. Identification and characterization of novel TRPV4 modulators. Biochem Biophys Res Commun 2009;389:490-4
77. Everaerts W, Nilius B, Owsianik G. The vanilloid transient receptor potential channel TRPV4: From structure to disease. Prog Biophys Mol Biol 2010;103:2-17
78. Alvarez DF, King JA, Weber D, et al. Transient receptor potential vanilloid 4-mediated disruption of the alveolar septal barrier: A novel mechanism of acute lung injury. Circ Res 2006;99:988-95 (Pubitemid 44657802)
79. Gevaert T, Vriens J, Segal A, et al. Deletion of the transient receptor potential cation channel TRPV4 impairs murine bladder voiding. J Clin Invest 2007;117:3453-62 (Pubitemid 350097001)
80. Todaka H, Taniguchi J, Satoh J, et al. Warm temperature-sensitive transient receptor potential vanilloid 4 (TRPV4) plays an essential role in thermal hyperalgesia. J Biol Chem 2004;279:35133-8 (Pubitemid 39100509)
81. Grant AD, Cottrell GS, Amadesi S, et al. Protease-activated receptor 2 sensitizes the transient receptor potential vanilloid 4 ion channel to cause mechanical hyperalgesia in mice. J Physiol 2007;578:715-33 (Pubitemid 46165505)
82. Alessandri-Haber N, Dina OA, Joseph EK, et al. A transient receptor potential vanilloid 4-dependent mechanism of hyperalgesia is engaged by concerted action of inflammatory mediators. J Neurosci 2006;26:3864-74
83. Earley S, Heppner TJ, Nelson MT, et al. TRPV4 forms a novel Ca2+ signaling complex with ryanodine receptors and BKCa channels. Circ Res 2005;97:1270-9
84. Muramatsu S, Wakabayashi M, Ohno T, et al. Functional gene screening system identified TRPV4 as a regulator of chondrogenic differentiation. J Biol Chem 2007;282:32158-67 (Pubitemid 350106454)
85. Jin M, Wu Z, Chen L, et al. Determinants of TRPV4 activity following selective activation by small molecule agonist GSK1016790A. PLoS One 2011;6:e16713
86. GlaxoSmithLine LLC. TRPV4 antagonist. WO146182; 2009
87. GlaxoSmithLine LLC. TRPV4 antagonist. WO146177; 2009
88. GlaxoSmithLine LLC. TRPV4 antagonist. WO111680; 2009
89. GlaxoSmithLine LLC. TRPV4 antagonist. WO011914; 2010
90. GlaxoSmithLine LLC. TRPV4 antagonist. WO011912; 2010
91. GlaxoSmithLine LLC. TRPV4 antagonist. WO091407; 2011
92. GlaxoSmithLine LLC. TRPV4 antagonist. WO119694; 2011
93. GlaxoSmithLine LLC. TRPV4 antagonist. WO119693; 2011
94. GlaxoSmithLine LLC. TRPV4 antagonist. WO091410; 2011
95. Story GM, Peier AM, Reeve AJ, et al. ANKTM1, a TRP-like channel expressed in nociceptive neurons, is activated by cold temperatures. Cell 2003;112:819-29. This paper reports the discovery of TRPA1. (Pubitemid 36378884)
96. Fajardo O, Meseguer V, Belmonte C, et al. TRPA1 channels mediate cold temperature sensing in mammalian vagal sensory neurons: Pharmacological and genetic evidence. J Neurosci 2008;28:7863-75
97. Peterlin Z, Chesler A, Firestein S. A painful trp can be a bonding experience. Neuron 2007;53:635-8 (Pubitemid 46283378)
98. Bautista DM, Movahed P, Hinman A, et al. Pungent products from garlic activate the sensory ion channel TRPA1. Proc Natl Acad Sci USA 2005;102:12248-52 (Pubitemid 41291160)
99. Jordt SE, Bautista DM, Chuang HH, et al. Mustard oils and cannabinoids excite sensory nerve fibres through the TRP channel ANKTM1. Nature 2004;427:260-5 (Pubitemid 38112043)
100. Bandell M, Story GM, Hwang SW, et al. Noxious cold ion channel TRPA1 is activated by pungent compounds and bradykinin. Neuron 2004;41:849-57 (Pubitemid 38429729)
101. Rawls SM, Gomez T, Ding Z, et al. Differential behavioral effect of the TRPM8/TRPA1 channel agonist icilin (AG-3-5). Eur J Pharmacol 2007;575:103
102. Karashima Y, Talavera K, Everaerts W, et al. TRPA1 acts as a cold sensor in vitro and in vivo. Proc Natl Acad Sci USA 2009;106:1273-8
103. Abrahamsen B, Zhao J, Asante CO, et al. The cell and molecular basis of mechanical, cold, and inflammatory pain. Science 2008;321:702-5. Interesting description of the underlying molecular and cellular basis of nociception and pain.
104. Kwan KY, Glazer JM, Corey DP, et al. TRPA1 modulates mechanotransduction in cutaneous sensory neurons. J Neurosci 2009;29:4808-19
105. Bessac BF, Sivula M, von Hehn CA, et al. Transient receptor potential ankyrin 1 antagonists block the noxious effects of toxic industrial isocyanates and tear gases. FASEB J 2009;23:1102-14
106. Talavera K, Gees M, Karashima Y, et al. Nicotine activates the chemosensory cation channel TRPA1. Nat Neurosci 2009;12:1293-9
107. Andre E, Campi B, Materazzi S, et al. Cigarette smoke-induced neurogenic inflammation is mediated by alpha, beta-unsaturated aldehydes and the TRPA1 receptor in rodents. J Clin Invest 2008;118:2574-82 (Pubitemid 351949784)
108. Glenmark Pharmaceuticals SA. Compounds as TRPA1 modulators. WO109334; 2010
109. Glenmark Pharmaceuticals SA. Imidazo [2,1-b]purine derivatives as TRPA1 modulators. WO144548; 2009
110. Glenmark Pharmaceuticals SA. Quinazolinedione derivatives as TRPA1 modulators. WO004390; 2010
111. Glenmark Pharmaceuticals SA. Compounds as TRPA1 modulators. WO125469; 2010
112. Glenmark Pharmaceuticals SA. Compounds as TRPA1 modulators. WO109328; 2010
113. Glenmark Pharmaceuticals SA. Compounds as TRPA1 modulators. WO109329; 2010
114. Glenmark Pharmaceuticals SA. Compounds as TRPA1 modulators. WO132017; 2010
115. Glenmark Pharmaceuticals SA. Compounds as TRPA1 modulators. WO132017; 2011
116. Hydra Biosciences I. Methods and compositions for treating disorders. WO140519; 2009
117. Hydra Biosciences I. Compounds and compositions for treating chemical warfare agent-inducing injuries. WO002933; 2009
118. Hydra Biosciences I. Methods and compositions for treating disorders. WO158719; 2009
119. Hydra Biosciences I. Compositions useful for treating disorders related to TRPA1. WO075353; 2010
120. Hydra Biosciences I. Compounds useful for treating disorders related to TRPA1. WO132838; 2010
121. Hydra Biosciences I. Compounds useful for treating disorders related to TRPA1. WO138879; 2010
122. Hydra Biosciences I. Methods and compositions for treating respiratory disorders. WO036821; 2010
123. Glenmark Pharmaceuticals SA. Imidazo [2,1-b]purine derivatives as TRPA1 modulators. WO144548; 2009
124. Baraldi PG, Romagnoli R, Saponaro G, et al. 7-Substituted-pyrrolo[3,2-d] pyrimidine-2,4-dione derivatives as antagonists of the transient receptor potential ankyrin 1 (TRPA1) channel: A promising approach for treating pain and inflammation. Bioorg Med Chem 2012;20:1690-8
125. Janssen Pharmaceutica NV. 3,4-Dihydropyrimidine TRPA1 antagonists. WO147079; 2009
126. Janssen Pharmaceutica NV. Heterocyclic amides as modulators of TRPA1. WO141805; 2010
127. Glenmark Pharmaceuticals SA. Quinazolinedione derivatives as TRPA1 modulators. WO004390; 2010
128. Gijsen HJ, Berthelot D, De Cleyn MA, et al. Tricyclic 3,4-dihydropyrimidine-2- thione derivatives as potent TRPA1 antagonists. Bioorg Med Chem Lett 2012;22:797-800
129. Abbott Laboratories. TRPA1 antagonists. WO089082; 2009
130. Abbott Laboratories. TRPA1 antagonists. WO089083; 2009
131. DeFalco J, Steiger D, Gustafson A, et al. Oxime derivatives related to AP18: Agonists and antagonists of the TRPA1 receptor. Bioorg Med Chem Lett 2010;20:276-9
132. Merck Sharp & Dohmr C. Novel TRPA1 antagonists. WO043954; 2011
133. Korea University. Compounds for inhibiting TRPA1 function and use thereof. US0137259; 2010
134. Bang S, Yoo S, Yang TJ, et al. Isopentenyl pyrophosphate is a novel antinociceptive substance that inhibits TRPV3 and TRPA1 ion channels. Pain 2011;152:1156-64
135. Korea University. TRPA1 inhibitor and its application as an analgesic (CA title). KR0323; 2011
136. AstraZeneca AB. TRPA1 antagonist. WO050512; 2012
137. Liu Y, Qin N. TRPM8 in health and disease: Cold sensing and beyond. Adv Exp Med Biol 2011;704:185-208. Interesing review on the implication of TRPM8 in human health and disease.
138. Knowlton WM, McKemy DD. TRPM8: From cold to cancer, peppermint to pain. Curr Pharm Biotechnol 2011;12:68-77. Interesing review on the implication of TRPM8 in human health and disease.
139. Babes A, Ciobanu AC, Neacsu C, et al. TRPM8, a sensor for mild cooling in mammalian sensory nerve endings. Curr Pharm Biotechnol 2011;12:78-88
140. Chuang HH, Neuhausser WM, Julius D. The super-cooling agent icilin reveals a mechanism of coincidence detection by a temperature-sensitive TRP channel. Neuron 2004;43:859-69 (Pubitemid 39215016)
141. Proudfoot CJ, Garry EM, Cottrell DF, et al. Analgesia mediated by the TRPM8 cold receptor in chronic neuropathic pain. Curr Biol 2006;16:1591-605 (Pubitemid 44233290)
142. Xing H, Chen M, Ling J, et al. TRPM8 mechanism of cold allodynia after chronic nerve injury. J Neurosci 2007;27:13680-90 (Pubitemid 350278250)
143. Tsavaler L, Shapero MH, Morkowski S, et al. Trp-p8, a novel prostate-specific gene, is up-regulated in prostate cancer and other malignancies and shares high homology with transient receptor potential calcium channel proteins. Cancer Res 2001;61:3760-9. This article reports the association of TRPM8 to cancer prostate, before of knowing that it was a cold activated receptor. (Pubitemid 32694990)
144. Yamamura H, Ugawa S, Ueda T, et al. TRPM8 activation suppresses cellular viability in human melanoma. Am J Physiol Cell Physiol 2008;295:C296-301 (Pubitemid 352755761)
145. McKemy DD. Therapeutic potential of TRPM8 modulators. Open Drug Discov J 2010;2:81-8
146. Malkia A, Morenilla-Palao C, Viana F. The emerging pharmacology of TRPM8 channels: Hidden therapeutic potential underneath a cold surface. Curr Pharm Biotechnol 2011;12:54-67
147. Moran MM, McAlexander MA, Biro T, et al. Transient receptor potential channels as therapeutic targets. Nat Rev Drug Discov 2011;10:601-20
148. Hydra Biosciences I. Compounds and compositions for treating chemical warfare agent-inducing injuries. WO002933; 2009
149. Janssen Pharmaceutica NV. Sulfonamides as TRPM8 Modulators. WO012430; 2009
150. Janssen Pharmaceutica NV. Radiolabelled TRPM8 receptor ligands. WO009220; 2010
151. Janssen Pharmaceutica NV. Sulfonamides as TRPM8 Modulators. US0160289; 2010
152. Janssen Pharmaceutica NV. Sulfamides as TRPM8 Modulators. WO080397; 2010
153. Janssen Pharmaceutica NV. Cold menthol receptor-1 antagonists. US0053347; 2012
154. Hydra Biosciences I. Methods and compositions for treating disorders. WO140519; 2009
155. Janssen Pharmaceutica NV. Sulfonamides as TRPM8 Modulators. WO080398; 2010
156. Parks DJ, LaFrance LV, Calvo RR, et al. 1,4-Benzodiazepine-2,5-diones as small molecule antagonists of the HDM2-p53 interaction: Discovery and SAR. Bioorg Med Chem Lett 2005;15:765-70
157. Janssen Pharmaceutica NV. Benzimidazole derivatives useful as TRPM8 receptor modulators. WO144679; 2010
158. Janssen Pharmaceutica NV. Benzimidazole derivatives useful as TRPM8 receptor modulators. WO144680; 2010
159. Janssen Pharmaceutica NV. Cold menthol receptor antagonists. WO021878; 2010
160. Hydra Biosciences I. Compounds and compositions for treating chemical warfare agent-inducing injuries. WO140517; 2009
161. Amgen I. Condensed piperidine derivatives useful as vanilloid receptor ligands. WO038812; 2009
162. Amgen I. TRP-M8 receptor ligands and their use in treatments. WO073203; 2009
163. Tamayo NA, Bo Y, Gore V, et al. Fused piperidines as a novel class of potent and orally available transient receptor potential melastatin type 8 (TRPM8) antagonists. J Med Chem 2012;55:1593-611
164. Glenmark Pharmaceutica SA. Fused oxazole and thiazole derivatives as TRPMS modulators. WO010435; 2010
165. Glenmark Pharmaceutica SA. Spirocyclic piperidine derivatives as TRP8 modulators. WO103381; 2010
166. Raqualia Pharma I. Sulfamoyl benzoic acid derivatives as TRPM8 antagonists. WO125831; 2010
167. Raqualia Pharma I. Sulfamoyl benzoic acid heterocbicyclic derivatives as TRPM8 antagonists. WO042915; 2012
168. GW Pharma L. New use for cannabinoid-containg plant extracts. WO129258; 2018
169. Dendreon Coorporation. Small-molecule modulators of TRP-P8 activity. US0255185; 2008
170. Janssen Pharmaceutica NV. 3,4-Dihydropyrimidine TRPA1 antagonists. US0124666; 2011
171. Janssen Pharmaceutica NV. Sulfamides as TRPM8 Modulators. US0160337; 2010
172. Institute of Chinese Materia Medica. New use of Neferine. WO118675; 2010
173. Basf SE. Detection and use of low-molecular weight modulators of the cold-menthol receptor TRPM8. WO026094; 2010
174. Symrise AG BSE. Use of fisiological cooling active ingredients and agents containing such active ingredients. WO061330; 2011
175. Natural Cosmeticos SA. Antiperspirant compositions and methods for reducing perspiration in humans. WO017609; 2010
176. Gavva NR, Treanor JJ, Garami A, et al. Pharmacological blockade of the vanilloid receptor TRPV1 elicits marked hyperthermia in humans. Pain 2008;136:202-10. This report describes the hyperthermia that TRPV1 antagonists produced in humans.
177. Dimond P, Carlson K, Bouvier M, et al. G protein-coupled receptor modulation with pepducins: Moving closer to the clinic. Ann NY Acad Sci 2011;1226:34-49. This report describes the design and development of peptide-based allosteric modulators of GPCRs, an approach that has been applied to TRP channels.
178. Ji RR, Samad TA, Jin SA, et al. P38 MAPK activation by NGF in primary sensory neurons after inflammation increases TRPV1 levels and maintain hyperalgesia. Neuron 2002;36:57-68